Brief: Innate Pharma Announces Positive Data From Phase 2 Trial For Lacutamab

Innate Pharma SA

03/11/2023 06:17

Nov 3 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA ANNOUNCES NEW CLINICAL DATA FOR LACUTAMAB
AND
SAR443579/IPH6101 AT ASH 2023
    * POSITIVE RESULTS FROM TELLOMAK PHASE 2 TRIAL WITH
LACUTAMAB IN
HEAVILY PRETREATED PATIENTS WITH RELAPSED AND REFRACTORY SÉZARY
SYNDROME SELECTED FOR ORAL PRESENTATION
    * PRELIMINARY MONOTHERAPY LACUTAMAB PHASE 1B CLINICAL DATA
AND
PRE-CLINICAL COMBINABILITY DATA IN PATIENTS WITH PERIPHERAL
T-CELL LYMPHOMA

Source text for Eikon:  urn:newsml:reuters.com:*:nBw44ShwQa
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))